Blue Cloud Softech Solutions Limited (BCSSL) announced the launch of its BluHealth Platform v2.0, an AI-integrated, enterprise-grade healthcare solution designed for large-scale deployment, as the company expands its footprint in the global digital health industry.
The BluHealth Platform v2.0 builds upon its earlier proof-of-concept by integrating advanced AI-driven clinical decision support, instant medical interpretations, intelligent care routing, and non-invasive diagnostics. Notable innovations include 60-second facial scan screenings, non-invasive HbA1c testing, and rugged, field-ready hardware, making it suitable for use in underserved communities and disaster zones.
The platform is fully interoperable, HIPAA/GDPR compliant, and aligns with universal health coverage initiatives. The company highlighted strong potential demand, with a pipeline that could contribute up to $6 million in business.
Key features:
-
AI Screening Ecosystem: Real-time clinical decision support and intelligent care routing.
-
Remote Vital Signs Monitoring: Using facial scanning, multi-sensor hardware (ECG, EMG, PPG, GSR), and rPPG technology for non-invasive readings.
-
Hardware Development: Rugged, portable devices integrated with software for institutional deployment.
-
Population Health Management: Dashboard for large-scale health trends, chronic disease management, and mobile campaigns.
-
Compliance & Security: Adherence to HIPAA and GDPR standards, designed for regulatory approval at national scale.
-
Rapid Diagnostics: AI-driven triage for early detection, cost-efficient, and emergency-ready.
Chairperson Janaki Yarlagadda said:
“We are proud to unveil BluHealth Platform, which embodies our vision for accessible, scalable, and intelligent digital health solutions. This launch strengthens our commitment to bridging care gaps for underserved communities and advancing universal health coverage with transformative technology.”
According to industry estimates (Grand View Research), the global digital health industry—valued at $288.55 billion in 2024—is projected to reach $946.04 billion by 2030, growing at a CAGR of 22.22%. BluHealth is positioned to capitalize on this growth, with particular traction expected in Middle Eastern and African markets.
